GSK to deploy BioClinica's Trident IWR system across Phase I-IV clinical trials

BioClinica^®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, today announced that GlaxoSmithKline LLC ("GSK") has signed a multi-year enterprise technology agreement to deploy BioClinica's Trident IWR (Interactive Web Response) system across its Phase I-IV clinical trials.

“We look forward to supporting GSK so that they can successfully deploy and utilize our software in their upcoming studies.”

"GSK had a requirement for a new solution to enable internal staff to configure and manage highly complex IWR clinical studies, and we are pleased GSK chose Trident," said Mark Weinstein, CEO of BioClinica. "We look forward to supporting GSK so that they can successfully deploy and utilize our software in their upcoming studies."

Trident IWR's unique design provides clinical operations personnel with an intuitive way to directly set up, monitor, and maintain randomization and supplies for their clinical trials, in a fraction of the time previously required. Trident IWR delivers rapid study setup without the need for programming, while simultaneously delivering world-class IVR (Interactive Voice Response) system phone support through the same simplified configuration process.